Sanofi SA

Затворен

СекторЗдравеопазване

84.57 -0.21

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

84.09

Максимум

84.94

Ключови измерители

By Trading Economics

Приходи

1.1B

2.9B

Продажби

129M

11B

P/E

Средно за сектора

16.656

37.257

EPS

1.59

Дивидентна доходност

4.52

Марж на печалбата

27.303

Служители

82,878

EBITDA

-881M

1.9B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+24.85% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.52%

2.94%

Следващи печалби

24.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

463M

105B

Предишно отваряне

84.78

Предишно затваряне

84.57

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.10.2025 г., 08:42 ч. UTC

Значими двигатели на пазара

U.K. Bank Shares Rise After Regulator Softens Car-Loan Redress Estimate

3.10.2025 г., 10:40 ч. UTC

Придобивния, сливания и поглъщания

Santander UK CEO Stands Down Ahead of TSB Integration

1.10.2025 г., 08:54 ч. UTC

Значими двигатели на пазара

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

4.09.2025 г., 08:58 ч. UTC

Значими двигатели на пазара

Sanofi Shares Sink as Experimental Drug Results Disappoint

4.08.2025 г., 10:06 ч. UTC

Значими двигатели на пазара

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31.07.2025 г., 06:00 ч. UTC

Печалби

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

6.10.2025 г., 08:15 ч. UTC

Пазарно говорене

Sanofi's Profitability Stronger Than It Looks -- Market Talk

3.10.2025 г., 14:10 ч. UTC

Пазарно говорене

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

3.10.2025 г., 10:06 ч. UTC

Придобивния, сливания и поглъщания

Santander's Regnier Says He Is Leaving to Allow Successor to Lead TSB Integration

3.10.2025 г., 10:03 ч. UTC

Придобивния, сливания и поглъщания

Santander: Appointment Process to Find Successor Has Started

3.10.2025 г., 10:02 ч. UTC

Придобивния, сливания и поглъщания

Santander: Mike Regnier to Step Down by 1Q 2026

3.10.2025 г., 10:01 ч. UTC

Придобивния, сливания и поглъщания

Santander UK CEO to Step Down

1.10.2025 г., 07:53 ч. UTC

Пазарно говорене

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

5.09.2025 г., 08:24 ч. UTC

Пазарно говорене

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5.09.2025 г., 06:55 ч. UTC

Пазарно говорене

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

28.08.2025 г., 09:00 ч. UTC

Пазарно говорене

Santander Could Deliver Even Higher Returns -- Market Talk

6.08.2025 г., 05:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Completes the Acquisition of Vigil Neuroscience

6.08.2025 г., 05:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1.08.2025 г., 13:16 ч. UTC

Печалби

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1.08.2025 г., 12:40 ч. UTC

Печалби

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31.07.2025 г., 08:15 ч. UTC

Пазарно говорене
Печалби

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31.07.2025 г., 05:56 ч. UTC

Пазарно говорене
Печалби

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi 2Q Business Operating Profit EUR2.46B

31.07.2025 г., 05:30 ч. UTC

Печалби

Sanofi 2Q Adj EPS EUR1.59

31.07.2025 г., 05:30 ч. UTC

Печалби

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

Sanofi SA Прогноза

Ценова цел

By TipRanks

24.85% нагоре

12-месечна прогноза

Среден 105.92 EUR  24.85%

Висок 121.052 EUR

Нисък 92.806 EUR

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

12

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

91.3 / 96.1Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat